Squarepoint’s Unity Biotechnology UBX Stock Holding History

Squarepoint’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,332	Closed	-$33.1K	–	5437
2024 Q4	$17.9K	Buy	+18,332	New	+$22.8K	﹤0.01%	4942
2024 Q2	–	Sell	-13,938	Closed	-$22.9K	–	4671
2024 Q1	$22.9K	Buy	+13,938	New	+$24.2K	﹤0.01%	3918
2022 Q3	–	Sell	-1,053	Closed	-$6K	–	3460
2022 Q2	$6K	Buy	+1,053	New	+$8.79K	﹤0.01%	2801
2021 Q2	–	Sell	-1,475	Closed	-$88K	–	3712
2021 Q1	$88K	Sell	1,475 -1,485	-50%	-$101K	﹤0.01%	2927
2020 Q4	$155K	Buy	+2,960	New	+$143K	﹤0.01%	2609
2020 Q3	–	Sell	-3,228	Closed	-$280K	–	2852
2020 Q2	$280K	Sell	3,228 -697	-18%	-$51.7K	﹤0.01%	1639
2020 Q1	$228K	Sell	3,925 -1,548	-28%	-$97.6K	0.01%	1416
2019 Q4	$395K	Buy	5,473 +4,137	+310%	+$292K	﹤0.01%	1899
2019 Q3	$82K	Buy	+1,336	New	+$94.5K	﹤0.01%	2210

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's UBX Position: Q1 2025 in Review

Squarepoint sold out of Unity Biotechnology (UBX) in Q1 2025, closing a stake of 18,332 shares — an estimated $33.1K sold.

Squarepoint first reported a position in UBX in Q3 2019 and held it in 9 quarters. The position peaked at $395K in Q4 2019. 40 funds tracked by Wall St. Rank hold UBX as of Q1 2025.

Squarepoint reported no remaining Unity Biotechnology position as of Q1 2025 after selling out during the quarter.
Squarepoint sold 18,332 Unity Biotechnology shares in Q1 2025, an estimated $33.1K.
Squarepoint first reported a position in Unity Biotechnology in Q3 2019 and held it in 9 quarters.
Squarepoint's Unity Biotechnology position peaked at $395K in Q4 2019.
40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.